Teva Pharmaceutical Industries Ltd
Close on Oct 19, 2026Market cap $48.13BP/E 68.9Yield –
Teva Pharmaceutical Industries Adjusted EBITDA (Non-GAAP) by Quarter
Adjusted EBITDA (Non-GAAP) ($M)
Teva Pharmaceutical Industries Adjusted EBITDA (Non-GAAP): $1,496M in Q3 2026, up 7.3% from a year earlier.
Where the Q3 2026 figure comes from
“|| Adjusted EBITDA | $ | 1,496 | 1,394 | $ | 3,025 | 3,668”
Source: Form 8-K Earnings Release (0001171843-26-007054) ↗
Non-GAAP Operating Income plus depreciation expense, reconciled from GAAP net income (loss) in Form 8-K earnings releases.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up adjusted EBITDA (Non-GAAP)
- EBITDA (GAAP Operating Income + Depreciation & Amortization)959 · Q3 2026
- Non-GAAP Gross Profit2,580 · Q3 2026
- Non-GAAP Gross Profit Margin (%)58.7% · Q3 2026
- GAAP Gross Profit (Per Non-GAAP Reconciliation Table)2,440 · Q3 2026
- GAAP Gross Profit Margin (%)55.5% · Q3 2026
- Non-GAAP Operating Income1,393 · Q3 2026
- GAAP Operating Income / (Loss) Margin (%)16.2% · Q3 2026
- Non-GAAP Net Income Attributable to Teva1,013 · Q3 2026
- Non-GAAP Diluted EPS Attributable to Teva–
- Non-GAAP Diluted Weighted Average Shares1,183 · Q3 2026
- Non-GAAP Effective Tax Rate (%)16.5% · Q3 2026
- Depreciation Expense (Per EBITDA Reconciliation)106 · Q3 2026
- Amortization of Purchased Intangible Assets (Per Non-GAAP Reconciliation)139 · Q3 2026
Cite this data
StockData. (2026). Teva Pharmaceutical Industries Adjusted EBITDA (Non-GAAP) ($M), quarterly Q4 2021–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/ng-adj-ebitda
See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.
See a number that looks wrong?